Results 221 to 230 of about 51,359 (249)
Triple-Negative Breast Cancer: Molecular Subtypes; Immune Escape; Limitations of Current Immunotherapy; and the BTLA/HVEM/CD160 Axis as an Emerging Target. [PDF]
Curr Issues Mol BiolRapoport BL +6 more
europepmc +1 more source
Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Seminars in Cancer Biology, 2022
Triple-negative breast cancer (TNBC) is a broad collection of breast cancer that tests negative for estrogen receptors (ER), progesterone receptors (PR), and excess human epidermal growth factor receptor 2 (HER2) protein. TNBC is considered to have poorer prognosis than other types of breast cancer because of a lack of effective therapeutic targets ...
Zhan Hua, Jason White, Jianjun Zhou
openaire +2 more sources
Triple-negative breast cancer (TNBC) is a broad collection of breast cancer that tests negative for estrogen receptors (ER), progesterone receptors (PR), and excess human epidermal growth factor receptor 2 (HER2) protein. TNBC is considered to have poorer prognosis than other types of breast cancer because of a lack of effective therapeutic targets ...
Zhan Hua, Jason White, Jianjun Zhou
openaire +2 more sources
The Achilles heel of TNBCs: Ferroptosis heterogeneity
Cell Metabolism, 2023Resistance to ferroptosis, a form of programmed cell death, is associated with the development of some refractory cancers. In this issue, Yang et al. systematically illustrate the ferroptosis heterogeneity in triple-negative breast cancers (TNBCs) and reveal an innovative immunotherapy combination strategy for the luminal androgen receptor (LAR ...
Li, Jiang, Xiao-Meng, Gao, Ji, Cao
openaire +2 more sources
Accelerating AXL targeting for TNBC therapy
The International Journal of Biochemistry & Cell Biology, 2021The tyrosine kinase receptor AXL of the TAM (TYRO3, AXL and MERTK) family is considered as a promising therapeutic target for different hematological cancers and solid tumors. AXL is involved in multiple pro-tumorigenic processes including cell migration, invasion, epithelial-mesenchymal transition (EMT), and stemness, and recent studies demonstrated ...
Lohit Khera, Sima Lev
openaire +2 more sources
Clinical Breast Cancer, 2016
Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer with poor 5-year survival. Knowledge and information about IBC with the triple negative (TNBC) phenotype are limited. Here, we report the characteristics and outcome of inflammatory TNBC (I-TNBC) cancer cohorts from a large TNBC dataset.After obtaining institutional review ...
Tithi Biswas +5 more
openaire +2 more sources
Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer with poor 5-year survival. Knowledge and information about IBC with the triple negative (TNBC) phenotype are limited. Here, we report the characteristics and outcome of inflammatory TNBC (I-TNBC) cancer cohorts from a large TNBC dataset.After obtaining institutional review ...
Tithi Biswas +5 more
openaire +2 more sources